Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.

Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

Abstract: Methods of determining the origin of cell free DNA (cfDNA), for detecting death of a cell type or tissue in a subject, for determining a cellular state of a cell as it died, and combinations thereof, are provided. As are computer program products for doing same.

Abstract: Methods of determining the origin of cell free DNA (cfDNA), for detecting death of a cell type or tissue in a subject, for determining a cellular state of a cell as it died, and combinations thereof, are provided. As are computer program products for doing same.

Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR ? chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR ? chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.

Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.

Abstract: Methods of determining the origin of cell free DNA (cfDNA), for detecting death of a cell type or tissue in a subject, for determining a cellular state of a cell as it died, and combinations thereof, are provided. As are computer program products for doing same.

Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

Abstract: Methods, computing systems and computer program products implement embodiments of the present invention that include configuring a storage system to store multiple storage entities for access by one or more host computers in communication with the storage system, and specifying a compression condition including a minimum compression ratio. The storage system can then estimate an expected compression ratio for a given storage entity, compress the given storage entity upon the expected compression ratio meeting the compression condition, and provide, to a given host computer, access to the compressed given storage entity.

Abstract: A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.

Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.

Abstract: Methods, computing systems and computer program products implement embodiments of the present invention that include configuring a storage system to store multiple storage entities for access by one or more host computers in communication with the storage system, and specifying a compression condition including a minimum compression ratio. The storage system can then estimate an expected compression ratio for a given storage entity, compress the given storage entity upon the expected compression ratio meeting the compression condition, and provide, to a given host computer, access to the compressed given storage entity.

Abstract: A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.

Abstract: A genetically modified bacteriophage is disclosed which comprises: (i) an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium; and (ii) an exogenous polynucleotide which encodes a selectable marker. Uses thereof and kits comprising same are also disclosed.

Abstract: A genetically modified bacteriophage is disclosed which comprises: (i) an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium; and (ii) an exogenous polynucleotide which encodes a selectable marker. Uses thereof and kits comprising same are also disclosed.

Abstract: The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque.

Abstract: Markers of multiple sclerosis and methods and kits utilizing same for diagnosing multiple sclerosis in an individual are provided.

Abstract: An acousto-optic scanning system, which relies on two counter propagating acoustic waves with the same frequency modulation. This scheme completely suppresses the linear frequency chirp, and thus enables the generation of fast non-linear scans and non-constant linear scans. By changing the phase between the modulating signals, this scheme also provides fast longitudinal scans of the focal point.

Abstract: An acousto-optic scanning system, which relies on two counter propagating acoustic waves with the same frequency modulation. This scheme completely suppresses the linear frequency chirp, and thus enables the generation of fast non-linear scans and non-constant linear scans. By changing the phase between the modulating signals, this scheme also provides fast longitudinal scans of the focal point.

Abstract: The invention comprises a method and apparatus for learning probabilistic models (PRM's) with attribute uncertainty. A PRM with attribute uncertainty defines a probability distribution over instantiations of a database. A learned PRM is useful for discovering interesting patterns and dependencies in the data. Unlike many existing techniques, the process is data-driven rather than hypothesis driven. This makes the technique particularly well-suited for exploratory data analysis. In addition, the invention comprises a method and apparatus for handling link uncertainty in PRM's. Link uncertainty is uncertainty over which entities are related in our domain. The invention comprises of two mechanisms for modeling link uncertainty: reference uncertainty and existence uncertainty. The invention includes learning algorithms for each form of link uncertainty. The third component of the invention is a technique for performing database selectivity estimation using probabilistic relational models.